(New York)

For several years Vanguard was seen as the champion of low-cost investing. It led the revolution in ever-lower cost ETFs. However, just recently, it seems to have fallen on hard times as it is facing challenges on multiple fronts. In particular, it is suffering at the hands of Fidelity, which is undercutting it on fund pricing. Fidelity’s recent no-fee index funds mean they are even cheaper than Vanguard’s lowest cost funds. The second, and perhaps even more worrisome challenge, relates to investment minimums, which Fidelity did away with on its cheapest funds. Vanguard’s minimums are now starting to look old-fashioned by comparison.

FINSUM: The best way for Vanguard to compete would be to merge some of the classes of their products. However, doing so would require a big revenue haircut, all of which means the company has some tough choices to make.

(New York)

Retail has had a great year, but looks to be facing headwinds moving forward as executives and analysts have all downgraded forecasts for the sector. However, one area of retail that looks to remain very hot are off-price stores, or discount retailers. Such retailers are seen as largely immune to ecommerce because of their treasure-hunt experience for customers and their high turnover model, which makes them less susceptible to online retailers. Accordingly, they held up well even during retail’s rout. One stock that looks likely to do well now is Burlington Stores. The reason why is that it is behind leaders TJ Max and Ross in that it has not yet optimized its operating model for the current environment, but is beginning to. This is not reflected in its stock, which means it has a great deal of upside.

FINSUM: Retail is one of the sectors we feel we have special insight into, and we definitely agree that off-price stores are going to hold up well moving forward.

(Washington)

There has been a lot of speculation that the midterm elections could cause a big problem for markets. If the Democrats sweep into congress, causing a major power shift, many worry markets might crumple. However, the reality is that the most likely outcome—a blue House and Red Senate—would actually be bullish for stocks. One analyst who specializes in political-driven investing says that investors would be relieved to have a split Congress. If somehow both chambers go blue, then there would likely be a selloff in bonds, stocks, and the Dollar, but even that might prove a buying opportunity as Democrats “are not unified around anything”.

FINSUM: Depending on the election’s outcome, different sectors are going to see different results, as some are blue-positive (like auto suppliers, homebuilders, hospitals etc), while others are red-positive (like biotech, banking, credit cards, and defense).

(New York)

This is a tough time to be buying bonds. Prices have become very rich over the last several years and on top of sky high valuations and low yields the risk of rising rates causing big losses is high as the Fed sticks to its hawkish path. With that in mind, floating rate bonds and ETFs are a good strategy to combat the situation, as their yields rise as the market’s do. Most also invest in short-term bonds to lessen interest rate risk. Two of the most popular floating rate ETFs are the iShares Floating Rate Bond ETF (FLOT) and SPDR Blmbg Barclays Inv Grd Flt Rt ETF (FLRN). Both hold floating rate bonds with maturities of 5 years and under.

FINSUM: These seem like good options. The one downside to these ETF is that yields are quite low given their conservative nature, but they obviously have great downside protection.

(New York)

Here is a proposition. What if you could have stocks in your portfolio that help you earn income, combat rising rates, and support you during a recession. Look no further than this group of rising dividends stocks that should perform very well in a recession. All three are medical device makers with wide moats and long growth runways that shouldn’t be thrown off path by an economic downturn. The three are Johnson & Johnson, Medtronic, and LeMaitre Vascular. The first two companies are aristocrats and have increased their dividends steadily for over 40 years.

FINSUM: These are interesting choices. Medical device makers do some like good recession-time bets because healthcare demand should hold up nicely in any downturn.